Applications are now open for the Children’s Tumor Foundation‘s (CTF) 2021 cycle of Drug Discovery Initiative Registered Reports (DDIRR) award program, a program to fund early stage testing of candidate drug therapies for neurofibromatosis treatment. This program is guided by the Registered Reports model, which involves pre-results peer review to align on scientific values and practices and encourages rigorous and reproducible science.
To facilitate this model, CTF and the publisher PLOS ONE have partnered together. DDIRR’s first output article, titled “Evaluating modified diets and dietary supplement therapies for reducing muscle lipid accumulation and improving muscle function in neurofibromatosis type 1 (NF1)”, was just published PLOS ONE in August 2020.
Letters of intent to apply for DDIRR are due December 14, 2020.
